Skip to main content
Premium Trial:

Request an Annual Quote

Immunis.AI Reaches $40M in Funding, Hits Key Milestones for Liquid Biopsy Platform

NEW YORK – Immunis.AI has closed a $10 million fundraising round, bringing its total financing to $40 million to date and met several key development milestones, including three pivotal studies of the Intelligentia liquid biopsy platform, the company announced on Wednesday.

The Intelligentia platform is designed to detect and grade early-stage cancers and other disorders via disease-specific biomarkers found in blood samples. It also assays for biomarkers of patients' immune response to disease.

The additional funding will support the validation and commercialization of the company's prostate cancer molecular test, as well as the continued development of tests for breast, colon, and lung cancers, among others.

Immunis.AI, formerly known as OncoCell MDx, had previously considered launching its prostate cancer surveillance laboratory-developed test in early 2021, following an independent validation study aimed for that same time period and fueled by a $22 million Series B financing round.

The global COVID-19 pandemic had affected sample collection, timing, and workflow related to that study. The company said via email that it has now completed enrollment and product analysis is underway. Immunis.AI now anticipates launching its test in late 2022.

"Immunis has developed a platform that harnesses the power of the immune system, achieving potent signal enrichment using proprietary methods and advanced machine learning," Harry Stylli, executive chairperson of the board at Immunis.AI. "With the recently achieved major milestones, the company is poised to deliver on its core mission to improve early detection and patient outcomes."

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.